SPINK9
Serine protease inhibitor Kazal-type 9
Also known as: ISK9_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q5DT21
- Gene
- SPINK9
- Ensembl
- ENSG00000204909
- Chromosome
- 5
- Canonical length
- 86 aa
- Protein class
- Predicted intracellular proteins, Predicted secreted proteins
- Subcellular location
- Nucleoplasm,Vesicles
- Secretome location
- Secreted in other tissues
OverviewNCBI Gene
The protein encoded by this gene is a Kazal-type serine protease inhibitor that appears to specifically target kallikrein-related peptidase 5 (KLK5) in the palmo-plantar epidermis. KLK5 is an important initiator of skin desquamation, so the encoded protease inhibitor may regulate skin differentiation in the palms of hands and soles of feet. This cationic protein has also been shown to promote keratinocyte migration by activation of the epidermal growth factor receptor (EGFR). [provided by RefSeq, Dec 2015]
Canonical amino-acid sequenceUniProt
86 residues, UniProt reviewed canonical sequence.
>Q5DT21|SPINK9
1 MRATAIVLLL ALTLATMFSI ECAKQTKQMV DCSHYKKLPP GQQRFCHHMY DPICGSDGKT
61 YKNDCFFCSK VKKTDGTLKF VHFGKCLocalizationUniProt · AlphaFold · HPA
Whether an antibody against SPINK9 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.42
- Highest tissue expression
- 2.6 nTPM
Expression across tissuesHPA
Tissue
- thymus: 2.6 nTPM
- bone marrow: 2.3 nTPM
- retina: 2 nTPM
- skeletal muscle: 0.9 nTPM
- testis: 0.8 nTPM
- skin: 0.7 nTPM
Single-cell type
- cardiomyocytes: 91 nCPM
- epicardial cells: 18 nCPM
- myonuclei: 6.6 nCPM
- adipocytes: 4.8 nCPM
- renal connecting tubule cells: 4.8 nCPM
- podocytes: 4.1 nCPM
Immune cell
- basophil: 6.4 nTPM
- neutrophil: 2.2 nTPM
- non-classical monocyte: 1.4 nTPM
- memory CD8 T-cell: 0.7 nTPM
- naive CD4 T-cell: 0.7 nTPM
- plasmacytoid DC: 0.7 nTPM
Brain region
- cerebral cortex: 34 nTPM
- white matter: 32 nTPM
- amygdala: 30 nTPM
- cerebellum: 30 nTPM
- hippocampal formation: 30 nTPM
- basal ganglia: 29 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.6
- gnomAD pLI
- 0.02
- gnomAD missense Z
- 0.26
- DepMap mean gene effect
- 0.1
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of SPINK9 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SPINK9 as an antibody target. Whether an autoantibody or antibody against SPINK9 could matter depends on whether native SPINK9 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SPINK9 is annotated as secreted, so native SPINK9 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label SPINK9 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...